Shanghai ZJ Bio-Tech Co., Ltd (SHA:688317)
China
· Delayed Price · Currency is CNY 20.43
+0.53 (2.66%)
Mar 10, 2026, 11:29 AM CST
Shanghai ZJ Bio-Tech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 124.91 | 175.52 | 270.87 | 2,263 | 1,993 | Upgrade
|
| Other Revenue | - | 3.13 | 3.46 | 63.59 | 25.37 | Upgrade
|
| Revenue | 124.91 | 178.65 | 274.33 | 2,326 | 2,019 | Upgrade
|
| Revenue Growth (YoY) | -30.08% | -34.88% | -88.21% | 15.23% | -1.62% | Upgrade
|
| Cost of Revenue | - | 216.07 | 282.13 | 1,131 | 762.4 | Upgrade
|
| Gross Profit | 124.91 | -37.42 | -7.8 | 1,196 | 1,256 | Upgrade
|
| Selling, General & Admin | - | 151.16 | 184.72 | 341.77 | 262.01 | Upgrade
|
| Research & Development | - | 58.78 | 61 | 104.62 | 108.79 | Upgrade
|
| Other Operating Expenses | 173.26 | 3.63 | 6.2 | 9.07 | 10.46 | Upgrade
|
| Operating Expenses | 173.26 | 221.98 | 253.27 | 461.8 | 386.64 | Upgrade
|
| Operating Income | -48.35 | -259.4 | -261.08 | 733.81 | 869.79 | Upgrade
|
| Interest Expense | - | -0.34 | -0.35 | -0.46 | - | Upgrade
|
| Interest & Investment Income | - | 113.26 | 67.54 | 42.54 | 17.16 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 14.38 | 17.82 | 65.8 | -13.86 | Upgrade
|
| Other Non Operating Income (Expenses) | 5.43 | -2.57 | -1.22 | 1.85 | -3.68 | Upgrade
|
| EBT Excluding Unusual Items | -42.92 | -134.67 | -177.29 | 843.55 | 869.4 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -5.94 | -1.36 | -0.06 | - | Upgrade
|
| Asset Writedown | - | -16.55 | - | - | -0.03 | Upgrade
|
| Other Unusual Items | - | 6.6 | 22.02 | 57.99 | 27 | Upgrade
|
| Pretax Income | -42.92 | -150.57 | -156.63 | 901.48 | 896.37 | Upgrade
|
| Income Tax Expense | -8.62 | -23.11 | -19.78 | 141.21 | 137.85 | Upgrade
|
| Earnings From Continuing Operations | -34.3 | -127.46 | -136.86 | 760.27 | 758.52 | Upgrade
|
| Net Income | -34.3 | -127.46 | -136.86 | 760.27 | 758.52 | Upgrade
|
| Net Income to Common | -34.3 | -127.46 | -136.86 | 760.27 | 758.52 | Upgrade
|
| Net Income Growth | - | - | - | 0.23% | -18.61% | Upgrade
|
| Shares Outstanding (Basic) | 181 | 190 | 193 | 193 | 191 | Upgrade
|
| Shares Outstanding (Diluted) | 181 | 190 | 193 | 193 | 191 | Upgrade
|
| Shares Change (YoY) | -5.10% | -1.30% | -0.36% | 1.51% | 30.46% | Upgrade
|
| EPS (Basic) | -0.19 | -0.67 | -0.71 | 3.93 | 3.98 | Upgrade
|
| EPS (Diluted) | -0.19 | -0.67 | -0.71 | 3.93 | 3.98 | Upgrade
|
| EPS Growth | - | - | - | -1.26% | -37.62% | Upgrade
|
| Free Cash Flow | - | 58.1 | -163.03 | 510.41 | 143.88 | Upgrade
|
| Free Cash Flow Per Share | - | 0.30 | -0.85 | 2.64 | 0.76 | Upgrade
|
| Dividend Per Share | - | 0.110 | - | 1.200 | 1.365 | Upgrade
|
| Dividend Growth | - | - | - | -12.09% | -14.69% | Upgrade
|
| Gross Margin | 100.00% | -20.95% | -2.84% | 51.40% | 62.23% | Upgrade
|
| Operating Margin | -38.71% | -145.20% | -95.17% | 31.55% | 43.08% | Upgrade
|
| Profit Margin | -27.46% | -71.35% | -49.89% | 32.68% | 37.57% | Upgrade
|
| Free Cash Flow Margin | - | 32.52% | -59.43% | 21.94% | 7.13% | Upgrade
|
| EBITDA | 17.34 | -193.72 | -197.63 | 790.85 | 894.63 | Upgrade
|
| EBITDA Margin | 13.88% | -108.43% | -72.04% | 34.00% | 44.31% | Upgrade
|
| D&A For EBITDA | 65.69 | 65.69 | 63.45 | 57.03 | 24.84 | Upgrade
|
| EBIT | -48.35 | -259.4 | -261.08 | 733.81 | 869.79 | Upgrade
|
| EBIT Margin | -38.71% | -145.20% | -95.17% | 31.55% | 43.08% | Upgrade
|
| Effective Tax Rate | - | - | - | 15.66% | 15.38% | Upgrade
|
| Revenue as Reported | - | 178.65 | 274.33 | 2,326 | 2,019 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.